Related Experiment Video

Updated: Feb 19, 2026

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

20.1K

The implications of CFTR structural studies for cystic fibrosis drug development

Isabelle Callebaut1, Brice Hoffmann1, Jean-Paul Mornon1

  • 1CNRS UMR7590, Sorbonne Universités, Université Pierre et Marie Curie - Paris 6 - MNHN - IRD - IUC, Paris, France.

Current Opinion in Pharmacology
|November 3, 2017
PubMed

Insights

Developing Cystic Fibrosis Transmembrane conductance Regulator (CFTR) modulators is complex due to diverse CFTR mutations and the need for protein stability. Structural data aids in understanding mutations and designing targeted CFTR therapies.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Genetics

Background:

  • Cystic Fibrosis (CF) is caused by mutations in the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene.
  • Developing effective CFTR modulators is challenging due to the wide range of CFTR mutation-associated phenotypes.
  • Personalized medicine approaches are needed for CF treatment.

Purpose of the Study:

  • To review the role of structural data in CFTR modulator development.
  • To understand disease mechanisms and CFTR protein function.
  • To guide the discovery of novel, specific CFTR-targeting compounds.

Main Methods:

  • Analysis of existing structural data for CFTR.
  • Characterization of CFTR mutation mechanisms.
  • Review of known CFTR modulator mechanisms of action.

Main Results:

  • Structural data provides insights into CFTR mutation effects.
  • Understanding CFTR protein dynamics is crucial for modulator design.
  • Structural information can rationalize the search for new CFTR therapies.

Conclusions:

  • Exploiting structural data is key to advancing CFTR modulator development.
  • Targeted therapies require a deep understanding of CFTR molecular mechanisms.
  • Structural biology is essential for personalized medicine in CF.

More Related Videos

Purification of the Cystic Fibrosis Transmembrane Conductance Regulator Protein Expressed in Saccharomyces cerevisiae15:12

Purification of the Cystic Fibrosis Transmembrane Conductance Regulator Protein Expressed in Saccharomyces cerevisiae

Published on: May 10, 2014

15.0K
Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein09:59

Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein

Published on: March 9, 2015

12.7K

Related Concept Videos

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
917
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
554
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
25
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
24